Redx Pharma wins Deal of the Year at Bionow Awards

Redx Pharma wins Deal of the Year at Bionow Awards

Redx Pharma Plc has won the coveted Deal of the Year award at the prestigious Bionow Awards for successfully raising £15 million listing on the London Stock Exchange’s (LSE) Alternative Investment Market (AIM) earlier this year.

The Bionow Awards recognise and celebrate excellence within the biomedical and life science sectors across Northern England, showcasing the very best of this world-class sector.

The company enjoyed a double win on the night, with Dr Peter Jackson, a non-executive director from Redx being recognised with Bionow’s Outstanding Contribution award.

The winners were announced at the prestigious Bionow Annual Awards Dinner on Thursday, November 26, which was attended by over 300 executives from across the biomedical industry.

Dr Neil Murray, Redx Pharma CEO, said: We’re delighted to have won this prestigious award and are grateful to the judges for recognising the vision, focus and effort which our team and advisers displayed — in particular our colleagues at Acceleris — and which culminated in successfully floating Redx Pharma on AIM in a difficult market. It was a pivotal moment for the business and we look forward to continuing to focus on growth and excellence through innovation.

The fact that Pete’s efforts and success have also been recognised with a well-deserved award on the night makes victory even sweeter and we’re delighted for him.

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.